Zivo Bioscience Inc (PK:ZIVO)

Business Focus: Special Foods & Welbeing Products

Sector:  Consumer Non-Cyclicals Industry:  Food Processing
 
See Regulatory Filings on SEC
Company Contact
Address: 21 E. Long Lake Road, Suite 100
BLOOMFIELD HILLS MI 48304
Tel: 1-212-2016614
Website: https://zivobioscience.com
IR: See website
<
Key People
John B. Payne
Chairman of the Board, President, Chief Executive Office, Director
Keith R. Marchiando
Chief Financial Officer
 
Business Overview
Zivo Bioscience, Inc. is a research and development company. The Company operates in both the biotech and agtech sectors, with an intellectual property portfolio comprised of algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques and patented or patent-pending inventions for applications in human and animal health. Its product candidates are at different stages of development for different applications. It is developing a product candidate targeting poultry gut health. It is developing products for Bovine Mastitis, Canine Joint Health, Human Immune Modulation, Algal biomass for human consumption, and Biomass for supporting skin health/anti-aging. It is focused on licensing and selling natural bioactive ingredients derived from their proprietary algae cultures to animal, human and dietary supplement, and medical food manufacturers.
Financial Overview
For the fiscal year ended 31 December 2023, Zivo Bioscience Inc revenues increased from $0K to $28K. Net loss decreased 11% to $7.8M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and Development decrease of 39% to $1.4M (expense), General and Administrative decrease of 9% to $5.9M (expense).
Employees: 8 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $19.13M as of Dec 31, 2023
Annual revenue (TTM): $0.03M as of Dec 31, 2023
EBITDA (TTM): -$7.26M as of Dec 31, 2023
Net annual income (TTM): -$7.78M as of Dec 31, 2023
Free cash flow (TTM): -$5.80M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 2,777,639 as of Mar 12, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.